Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthSource vs ShedRx

Two GLP-1 desks, one scoreboard. We put HealthSource and ShedRx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 51 · Grade C

HealthSource

Visit HealthSource Full brief →
vs
Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 79 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make HealthSource a bad call — it's best for readers who want compounded semaglutide or tirzepatide (injection or oral) in all 50 states from $199/mo. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
78
86
Supply Reliability
68
86
Transparency
88
84
Access Breadth
96
85
Clinical Oversight
81
85
Track Record
63
86
HealthSourceBrief Score 79 · 87ShedRx

Price, coverage & the tracker

HealthSourceShedRx
Brief Score79/100 (C)87/100 (B+)
SemaglutideFrom $199/mo (all doses, compounded)$199/mo
TirzepatideFrom $299/mo (all doses, compounded)$299/mo
CoverageAll 50 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingFallingprice falling

HealthSource: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.